MediWound Stock Earnings Estimates Raised by HC Wainwright

MediWound logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • HC Wainwright raised its FY2026 EPS estimate to a loss of $1.86 per share from a projected loss of $2.02; the broader consensus is a loss of $2.37 per share.
  • MediWound reported a quarterly loss of $0.65 per share, beating the $0.71 loss analysts expected, but revenue of $3.57 million fell short of the $6.73 million estimate.
  • Analyst sentiment is generally positive: four analysts rate MDWD a Buy and one a Sell, giving the stock a “Moderate Buy” consensus rating and an average price target of $33.
  • MarketBeat previews top five stocks to own in December.

MediWound Ltd. (NASDAQ:MDWD - Free Report) - HC Wainwright boosted their FY2026 earnings per share estimates for MediWound in a report issued on Friday, November 13th. HC Wainwright analyst S. Ramakanth now forecasts that the biopharmaceutical company will post earnings of ($1.86) per share for the year, up from their prior forecast of ($2.02). The consensus estimate for MediWound's current full-year earnings is ($2.37) per share. HC Wainwright also issued estimates for MediWound's Q4 2026 earnings at ($0.57) EPS, Q2 2027 earnings at ($0.58) EPS, Q3 2027 earnings at ($0.50) EPS, Q4 2027 earnings at ($0.45) EPS, FY2027 earnings at ($2.07) EPS, FY2028 earnings at ($1.18) EPS and FY2029 earnings at $0.51 EPS.

MDWD has been the topic of a number of other research reports. TD Cowen reissued a "buy" rating on shares of MediWound in a report on Thursday, September 24th. Wall Street Zen raised shares of MediWound from a "strong sell" rating to a "sell" rating in a report on Saturday, September 26th. Alliance Global Partners reaffirmed a "buy" rating on shares of MediWound in a report on Wednesday, September 16th. Weiss Ratings downgraded shares of MediWound from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Tuesday, September 8th. Finally, Oppenheimer reiterated an "outperform" rating and set a $30.00 price target (down from $32.00) on shares of MediWound in a research report on Friday, August 14th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $33.00.

Check Out Our Latest Research Report on MediWound

MediWound Trading Up 5.0%

Shares of MDWD opened at $13.55 on Tuesday. The company has a 50-day simple moving average of $13.21 and a 200-day simple moving average of $15.03. MediWound has a 52-week low of $11.80 and a 52-week high of $19.70.

MediWound (NASDAQ:MDWD - Get Free Report) last released its quarterly earnings data on Thursday, November 12th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.71) by $0.06. MediWound had a negative return on equity of 58.44% and a negative net margin of 234.98%. The firm had revenue of $3.57 million during the quarter, compared to analysts' expectations of $6.73 million.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in MediWound stock. Marshall Wace LLP bought a new stake in shares of MediWound Ltd. (NASDAQ:MDWD - Free Report) during the third quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 15,026 shares of the biopharmaceutical company's stock, valued at approximately $207,000. Marshall Wace LLP owned about 0.12% of MediWound as of its most recent filing with the SEC. Hedge funds and other institutional investors own 46.83% of the company's stock.

Insider Activity

In other news, COO Shmuel Hess sold 3,958 shares of the stock in a transaction that occurred on Thursday, August 27th. The shares were sold at an average price of $12.92, for a total value of $51,137.36. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 9.20% of the stock is owned by company insiders.

Top MediWound Stories

Investors following MDWD have been watching these stories:

  • Positive Sentiment: CEO and Chairman increased their holdings as a pivotal trial milestone approaches, a potentially supportive insider-confidence signal. Article: MediWound’s CEO and Chairman Increase Their Holdings as a Pivotal Trial Milestone Nears
  • Positive Sentiment: MediWound will host a December 2 KOL event on EscharEx’s Phase III VALUE study and commercial opportunity. The company cited estimated U.S. annual peak sales potential of $1.05 billion; the event may renew investor attention to the program, though it is not a new trial result. Company announcement: MediWound to Host Virtual KOL Event
  • Negative Sentiment: HC Wainwright cut multiple forward EPS estimates, including FY2027 to a loss of $2.07 per share from $2.00, FY2028 to a loss of $1.18 from $0.98, FY2029 profit to $0.51 from $0.75, and FY2030 profit to $1.95 from $2.25. These reductions point to a weaker expected earnings trajectory. The analyst modestly improved FY2026 and Q4 2026 estimates, but those upward revisions were limited. MarketBeat: MediWound analyst estimates

MediWound Company Profile

(Get Free Report)

MediWound Ltd. is an Israeli biotechnology company that develops topical enzymatic treatments for tissue repair. Its products are designed to remove damaged tissue and support care for patients with burns and chronic wounds. The company's lead product, NexoBrid, is a bromelain-based treatment used to remove dead tissue from deep thermal burns. It has received regulatory approvals in the United States and other markets. In the United States, MediWound works with Vericel to commercialize the product.

See Also

Earnings History and Estimates for MediWound (NASDAQ:MDWD)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in MediWound Right Now?

Before you consider MediWound, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MediWound wasn't on the list.

While MediWound currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines